Eagle Pharmaceuticals, Inc. (EGRX) Receives $62.33 Average PT from Brokerages

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) have earned an average rating of “Hold” from the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $62.33.

A number of research analysts recently weighed in on the company. BidaskClub downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Mizuho reissued a “sell” rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 9th. ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th.

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) traded down $0.08 during mid-day trading on Tuesday, hitting $58.84. The company had a trading volume of 111,488 shares, compared to its average volume of 166,918. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15. Eagle Pharmaceuticals has a 1-year low of $45.05 and a 1-year high of $97.15. The company has a market cap of $878.01, a P/E ratio of 9.49 and a beta of 1.24.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.50. Eagle Pharmaceuticals had a return on equity of 62.60% and a net margin of 36.95%. sell-side analysts predict that Eagle Pharmaceuticals will post 2.23 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of EGRX. Janus Henderson Group PLC bought a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at approximately $144,384,000. Old Mutual Global Investors UK Ltd. increased its position in Eagle Pharmaceuticals by 271.6% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 386,132 shares of the specialty pharmaceutical company’s stock worth $23,028,000 after buying an additional 282,225 shares during the period. Lazard Asset Management LLC increased its position in Eagle Pharmaceuticals by 1,045.7% in the 2nd quarter. Lazard Asset Management LLC now owns 278,108 shares of the specialty pharmaceutical company’s stock worth $21,939,000 after buying an additional 253,833 shares during the period. Prudential Financial Inc. increased its position in Eagle Pharmaceuticals by 808.7% in the 3rd quarter. Prudential Financial Inc. now owns 222,072 shares of the specialty pharmaceutical company’s stock worth $13,244,000 after buying an additional 197,634 shares during the period. Finally, State Street Corp increased its position in Eagle Pharmaceuticals by 23.7% in the 2nd quarter. State Street Corp now owns 696,466 shares of the specialty pharmaceutical company’s stock worth $54,949,000 after buying an additional 133,601 shares during the period.

TRADEMARK VIOLATION NOTICE: “Eagle Pharmaceuticals, Inc. (EGRX) Receives $62.33 Average PT from Brokerages” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://stocknewstimes.com/2018/01/21/eagle-pharmaceuticals-inc-egrx-receives-62-33-average-pt-from-brokerages.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply